Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
Evans et al.,
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital..,
Journal of Infection, doi:10.1016/j.jinf.2023.02.012
Retrospective high risk outpatients in the UK, showing lower hospitalization/death with sotrovimab treatment. Residual confounding is likely with adjustments having no detail on specific comorbidities.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.1 [Liu, Sheward, VanBlargan] and a lack of efficacy for BA.2 [Zhou]. US EUA has been revoked.
risk of death/hospitalization, 27.0% lower, HR 0.73, p = 0.03, treatment 1,079, control 4,973, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Evans et al., 25 Jan 2023, retrospective, United Kingdom, peer-reviewed, 11 authors, study period 16 December, 2021 - 22 April, 2022.
Contact:
andrew.evans@gov.wales, cathy.qi@swansea.ac.uk, j.o.adebayo@swansea.ac.uk, underwoodj7@cardiff.ac.uk, coulsonjm@cardiff.ac.uk, r.bailey@swansea.ac.uk, gareth.john@wales.nhs.uk, edwardsag@cardiff.ac.uk, coopera8@cardiff.ac.uk, r.a.lyons@swansea.ac.uk, a.akbari@swansea.ac.uk.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2023.01.24.23284916; this version posted January 25, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on
preventing hospital admission among higher-risk patients with COVID-19 in Wales: a
retrospective cohort study
Authors
Andrew Evans, Chief Pharmaceutical Officer, Health and Social Services Group, Welsh Government,
Cathays Park, Cardiff CF10 3NQ (corresponding author) Andrew.Evans@gov.wales
Cathy Qi, Statistician and Research Officer, Population Data Science, Swansea University Medical
School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea
SA2 8PP Cathy.Qi@swansea.ac.uk
Lolu Adebayo, Research Officer, Population Data Science, Swansea University Medical School,
Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea SA2 8PP
J.O.Adebayo@swansea.ac.uk
Jonathan Underwood, Clinical Academic Research Partnership Fellow, School of Medicine, Cardiff
University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
underwoodj7@cardiff.ac.uk
James Coulson, Clinical Reader, School of Medicine, Cardiff University, University Hospital of
Wales, Heath Park, Cardiff, CF14 4XN Coulsonjm@cardiff.ac.uk
Rowena Bailey, Senior Research Officer, Population Data Science, Swansea University Medical
School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park Swansea
SA2 8PP r.bailey@swansea.ac.uk
Gareth John, Information Systems Development and Design Lead, Information Services Directorate,
Digital Health and Care Wales, Tŷ Glan-yr-Afon, 21 Cowbridge Road East, Cardiff CF11 9AD
Gareth.John@wales.nhs.uk
Adrian Edwards, Professor of General Practice, Division of Population Medicine, Director, PRIME
Centre Wales and Wales COVID-19 Evidence Centre. Division of Population Medicine, Cardiff
University, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS Edwardsag@cardiff.ac.uk
Alison Cooper, Associate Academic Fellow, Wales Covid-19 Evidence Centre. Division of
Population Medicine, Cardiff University, Neuadd Meirionnydd, Heath Park, Cardiff, CF14 4YS
Coopera8@cardiff.ac.uk
Ronan A Lyons, Clinical Professor of Public Health, Population Data Science, Swansea University
Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Singleton Park
Swansea SA2 8PP r.a.lyons@swansea.ac.uk
Ashley Akbari, Associate Professor Population Data Science Research, Population Data Science,
Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea
University, Singleton Park Swansea SA2 8PP a.akbari@swansea.ac.uk
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2023.01.24.23284916; this version posted January 25, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Abstract
Objective
To compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab with..
evans2
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit